Abstract

To investigate the efficacy of the addition of atezolizumab combined with bevacizumab after radical resection in the treatment of hepatocellular carcinoma. This was a randomized controlled trial in which 84 patients with hepatocellular carcinoma treated with radical resection were enrolled. 43 patients were randomly assigned to receive trans catheter arterial chemoembolization and were classified as the control group (group C); the other 41 patients were randomly assigned to receive atezolizumab combined with bevacizumab treatment and were classified as research group (group R). Overall survival, recurrence-free survival, objective response rate, and the incidence of adverse events were compared between the two groups. In group R and group C, the median follow-up period was 8.6 mo and 8.2 mo, respectively. In comparison to group C, group R had significantly higher overall survival, recurrencefree survival, and risk ratio (p<0.05). The rate of negative reactions was greater in group R compared to group C (p<0.05). After radical resection of hepatocellular carcinoma, the addition of atezolizumab in combination with bevacizumab to transcatheter arterial chemoembolization significantly improves patients overall survival and recurrence-free survival with a high objective remission rate; however, this dosing regimen leads to a higher number of adverse effects, which need to be paid attention to.